About Us

Serentis is a privately owned biopharmaceutical company founded in 2006 with the objective of developing a pipeline of innovative proprietary products to address unmet medical needs in dermatology.

Serentis Management Team (from left to right): Gunnar Staaf, Dr Andy Baxter, Tim Sharpington, Peter Keen and Dr Alan Rothaul

Our strategy is to establish a clinical stage development pipeline and to move rapidly to proof-of-principle.  The pipeline is sourced both through our in-house, low-risk discovery function and through licensing and acquisition of external assets.  Products are selected based on the potential competitive advantage and the commercial opportunity they may provide in the US$11 billion global dermatology market1

The management team includes seasoned professionals with a strong track record of delivering fast, efficient development programmes with clear commercial positioning.

With significant financial backing from leading venture capitalists, Serentis has, in a short period of time, been able to develop products which promise to deliver value for patients in the area of dermatology.  Please do not hesitate to contact us if you need further information. 

Tim Sharpington, Chief Executive Officer.

[1] Business Insights, The Dermatology Market Outlook to 2011, Fox Analytics, 2007